Doxepin vs Trazodone
FDA Approved vs FDA Approved
monitor Researched · 90% Both doxepin and trazodone promote sleep through different mechanisms. Combining them can result in excessive sedation, prolonged next-day drowsiness, and additive CNS depression. Stacking multiple sleep aids is generally unnecessary and increases the risk of adverse effects. If transitioning between the two, allow adequate washout time.
Molecular Data
Doxepin Trazodone
Weight 279.38 Da 371.86 Da
Half-life ~15 hours ~5-9 hours
Type Tricyclic dibenzoxepin derivative (C19H21NO) Triazolopyridine derivative (C19H22ClN5O)
Key Benefits
Doxepin
01 FDA-approved specifically for sleep maintenance insomnia at ultra-low doses (3-6 mg as Silenor)
02 Highly selective H1 antihistamine at low doses, avoiding the side effects of traditional tricyclic antidepressants
03 Non-habit-forming with no dependence, tolerance, or abuse potential
04 No rebound insomnia upon discontinuation, unlike benzodiazepines and Z-drugs
05 Particularly effective for maintaining sleep in the latter half of the night, when many other sleep aids have worn off
06 Extremely well-tolerated side effect profile at ultra-low doses
Trazodone
01 Effective sleep aid that improves sleep onset and sleep maintenance without the dependence risk of benzodiazepines
02 Enhances slow-wave (deep) sleep, which is critical for physical recovery and growth hormone release
03 Non-habit-forming with no significant tolerance development, even with long-term use
04 Widely used and well-tolerated solution for trenbolone-induced and steroid-related insomnia
05 Does not suppress REM sleep the way many other sleep medications do
06 Inexpensive, widely available as a generic, and has decades of safety data
Side Effects
Doxepin
Morning drowsiness or grogginess (more common at the 6 mg dose; uncommon at 3 mg)
Dry mouth (mild at ultra-low doses, much less than at antidepressant doses)
Nausea
Upper respiratory tract infection (observed in clinical trials at rates similar to placebo)
Trazodone
Morning drowsiness or grogginess (dose-dependent, more common above 50 mg)
Dry mouth
Dizziness or lightheadedness, particularly upon standing (orthostatic hypotension)
Headache
Nausea (reduced by taking with food)
Blurred vision
Contraindications
Known hypersensitivity to doxepin or other dibenzoxepines
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
Untreated narrow-angle glaucoma
Severe urinary retention
Severe hepatic impairment (doxepin is extensively hepatically metabolized)
Known hypersensitivity to trazodone
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
History of priapism or conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia)
Severe hepatic impairment (dose adjustment required in moderate impairment)
Recent myocardial infarction or unstable cardiac conditions
Pregnancy, particularly first trimester (Category C; limited human data)
Research Evidence
Doxepin Trazodone
Status FDA Approved FDA Approved
References 4 studies 4 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.